Boston Trust Walden Corp Sells 30,903 Shares of Agilent Technologies, Inc. (NYSE:A)
Boston Trust Walden Corp cut its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 7.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 404,315 shares of the medi Boston Trust Walden Corp sold 30,903 shares of Agilent Technologies, Inc. (NYSE:A) in the 4th quarter, reducing its holdings in the company by 7.1%. The institutional investor now owns 404,315 shares of the medical research company's stock, worth $56,212,000. Other institutional investors and hedge funds have also made significant changes to their positions in the firm. Synovus Financial Corp grew its stake in shares by 2.3% in the 1st quarter. Blair William & Co. IL increased their stake in Agillent Technologies by 7%. Zions Bancorporation N.A. grew its holdings by 10.8% in first quarter. Several analysts have issued positive reviews on A shares.
Diterbitkan : sebulan yang lalu oleh MarketBeat di dalam Finance
Boston Trust Walden Corp cut its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 7.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 404,315 shares of the medical research company's stock after selling 30,903 shares during the period. Boston Trust Walden Corp owned approximately 0.14% of Agilent Technologies worth $56,212,000 at the end of the most recent reporting period.
• 3 Stocks About to Book Gains on Building Products Demand
Other institutional investors and hedge funds also recently made changes to their positions in the company. Synovus Financial Corp grew its stake in shares of Agilent Technologies by 2.3% in the 1st quarter. Synovus Financial Corp now owns 6,751 shares of the medical research company's stock worth $895,000 after acquiring an additional 153 shares in the last quarter. Blair William & Co. IL increased its stake in Agilent Technologies by 7.3% in the 1st quarter. Blair William & Co. IL now owns 28,606 shares of the medical research company's stock valued at $3,785,000 after buying an additional 1,957 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Agilent Technologies by 52.1% during the 1st quarter. Sequoia Financial Advisors LLC now owns 2,334 shares of the medical research company's stock worth $309,000 after buying an additional 799 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Agilent Technologies by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 24,531,170 shares of the medical research company's stock worth $3,246,209,000 after buying an additional 261,435 shares during the last quarter. Finally, Zions Bancorporation N.A. grew its holdings in shares of Agilent Technologies by 10.8% in the first quarter. Zions Bancorporation N.A. now owns 2,880 shares of the medical research company's stock valued at $381,000 after acquiring an additional 281 shares in the last quarter.
Several analysts have issued reports on A shares. UBS Group boosted their target price on Agilent Technologies from $130.00 to $155.00 and gave the company a "neutral" rating in a research note on Wednesday, February 28th. Bank of America downgraded shares of Agilent Technologies from a "buy" rating to a "neutral" rating and lifted their target price for the stock from $130.00 to $133.00 in a research note on Tuesday, December 12th. Barclays upped their price target on shares of Agilent Technologies from $120.00 to $125.00 and gave the company an "underweight" rating in a research note on Wednesday, February 28th. Evercore ISI lifted their price objective on shares of Agilent Technologies from $132.00 to $145.00 and gave the company an "in-line" rating in a research note on Thursday. Finally, The Goldman Sachs Group boosted their target price on shares of Agilent Technologies from $128.00 to $145.00 and gave the company a "buy" rating in a report on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $139.06.
Get Our Latest Report on Agilent Technologies
A stock traded down $2.37 on Thursday, reaching $141.36. 1,183,934 shares of the company traded hands, compared to its average volume of 1,624,921. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04. The firm has a fifty day simple moving average of $139.36 and a 200-day simple moving average of $127.36. Agilent Technologies, Inc. has a one year low of $96.80 and a one year high of $151.58. The company has a market cap of $41.43 billion, a P/E ratio of 34.34, a price-to-earnings-growth ratio of 4.36 and a beta of 1.11.
• Banks Think Small Cap Stocks Need to Catch Up: 3 Winners
Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.22 by $0.07. The company had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.59 billion. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The firm's revenue for the quarter was down 5.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.37 EPS. Research analysts anticipate that Agilent Technologies, Inc. will post 5.51 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd will be paid a dividend of $0.236 per share. The ex-dividend date of this dividend is Monday, April 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.67%. Agilent Technologies's dividend payout ratio is currently 22.38%.
In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the sale, the director now owns 54,976 shares in the company, valued at approximately $7,935,235.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of Agilent Technologies stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the transaction, the director now directly owns 54,976 shares of the company's stock, valued at approximately $7,935,235.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael R. Mcmullen sold 52,297 shares of the business's stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $150.00, for a total value of $7,844,550.00. Following the transaction, the chief executive officer now directly owns 253,909 shares in the company, valued at approximately $38,086,350. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,610 shares of company stock valued at $9,220,333.
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
• Five stocks we like better than Agilent Technologies
• What is a Bond Market Holiday? How to Invest and Trade
• 3 Stocks About to Book Gains on Building Products Demand
• What is a Low P/E Ratio and What Does it Tell Investors?
• Consumer Spending and Sentiment Rises: Time to Buy the XLY?
• Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
• Is Estée Lauder on the Verge Of a Massive Comeback?
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Should you invest $1,000 in Agilent Technologies right now?
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Topik: Markets